Pharmicell Co., Ltd. – Company Intelligence Brief

1. Business Overview

Pharmicell Co., Ltd. (KOSDAQ: 005690) is a Korean biopharmaceutical company. Based on the filing data provided, the company generates revenue through pharmaceutical operations, reporting KRW 64.9 billion in sales for fiscal year 2024 (FY57, ending December 31, 2024).

[TRANSLATION NOTE] The company name and business segment details are translated from Korean DART filings. Specific product lines, therapeutic areas, and operational divisions are not detailed in the financial data provided and may require verification against Korean-language disclosures for precision.

2. Financial Trend

Pharmicell demonstrates positive revenue momentum with sales growing 15.3% year-over-year from KRW 56.2 billion (FY56/2023) to KRW 64.9 billion (FY57/2024). This follows relatively flat performance in the prior period (KRW 60.2 billion in FY55/2022).

Operating profitability improved substantially: operating profit surged 259% from KRW 1.3 billion (2023) to KRW 4.7 billion (2024), though still below the KRW 8.9 billion recorded in 2022. The operating margin expanded to 7.2% in 2024 versus 2.3% in 2023. Net income increased 77% to KRW 6.3 billion in 2024 from KRW 3.6 billion in 2023.

The balance sheet is healthy with total assets of KRW 99.3 billion and total liabilities of only KRW 12.8 billion as of December 2024, yielding a debt-to-equity ratio of 14.8%. Notably, retained earnings turned positive at KRW 7.1 billion in 2024 after recording KRW 1.1 billion in 2023, recovering from a massive accumulated deficit of negative KRW 146.9 billion in 2022—suggesting a significant equity restructuring or capital event occurred between FY55 and FY56.

3. Ownership Structure

The financial statements provided do not include ownership or shareholder structure data. Foreign ownership percentage and controlling shareholder information are not disclosed in the DART balance sheet and income statement extracts supplied. This information would typically appear in separate disclosure documents (주식소유현황 reports) not included in this dataset.

4. Key Risks

Revenue concentration risk: With the data showing only aggregate revenue figures without segment breakdown, the company may face concentration risk if revenue depends heavily on a limited number of products or customers, common in specialized biopharmaceutical firms.

Operating leverage volatility: Operating profit swung from KRW 8.9 billion (2022) to KRW 1.3 billion (2023) to KRW 4.7 billion (2024) despite relatively stable revenue, indicating high fixed costs and significant earnings sensitivity to revenue fluctuations—a 15% revenue increase drove a 259% operating profit increase.

5. Investment Consideration

Pharmicell shows improving profitability and a clean balance sheet after apparent restructuring, but volatile operating margins and lack of disclosed business segment diversification warrant careful assessment of the sustainability of its 2024 earnings recovery.